Close Menu

This article has been updated to clarify the source of some quotes, which were from the company's President and CEO Daniel Forche.

NEW YORK (360Dx) – PreludeDx, a diagnostics firm advancing an assay for early breast cancer, shared results from a clinical validation of its test called DCISionRT at this week's San Antonio Breast Cancer Symposium that demonstrated it could have use as a tool to stratify patients who may respond to radiation.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.